Global Patent Index - EP 0973904 A1

EP 0973904 A1 2000-01-26 - COMPOSITIONS AND USE OF M-CSF-alpha

Title (en)

COMPOSITIONS AND USE OF M-CSF-alpha

Title (de)

Zusammensetzungen und Verwendungen von M-CSF-alpha

Title (fr)

COMPOSITIONS ET UTILISATIONS DE M-CSF-alpha

Publication

EP 0973904 A1 (EN)

Application

EP 98910322 A

Priority

  • US 9804802 W
  • US 3858397 P

Abstract (en)

[origin: WO9839449A1] The invention is a method and composition for reducing a population of diseased cells by administration of a gene delivery vehicle capable of expressing an M-CSF alpha mutant having a decreased capacity to be proteolytically processed and released from a cell membrane. The invention is also a combination of therapeutic agents including gene delivery vehicles expressing M-CSF alpha or an M-CSF alpha mutant in combination, for example, either with a soluble M-CSF, an M-CSF alpha convertase inhibitor, or a gene delivery vehicle expressing prodrug activator such as thymidine kinase followed by administration of the prodrug.

IPC 1-7

C12N 15/27; A61K 38/19; A61K 48/00; C07K 14/53

IPC 8 full level

C12N 15/09 (2006.01); A61K 35/76 (2006.01); A61K 38/00 (2006.01); A61K 38/19 (2006.01); A61K 48/00 (2006.01); A61P 35/00 (2006.01); C07K 14/53 (2006.01); C12N 5/10 (2006.01); C12N 15/27 (2006.01)

CPC

A61K 38/193 (2013.01); C07K 14/53 (2013.01); A61K 48/00 (2013.01); C12N 2799/022 (2013.01); Y02A 50/409 (2018.01)

C-Set

A61K 38/193 + A61K 2300/00

Citation (search report)

See references of WO 9839449A1

DCS

AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family

WO 9839449 A1 19980911; AU 6458898 A 19980922; EP 0973904 A1 20000126; JP 2001517079 A 20011002